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Abstract: Tilmicosin (TLM) is a semisynthetic antimicrobial agent used mainly in poultry and cattle, but it has relatively poor oral
bioavailability. This study was conducted to compare the bioavailability (BA) and main pharmacokinetic (PK) parameters of TLM
after oral administration of tilmicosin phosphate (TLM-PH) and three newly prepared lipid nanoparticles (LNPs) of TLM including
solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid-core nanocapsules (LNCs). Sixty broiler chickens were
divided into eight groups. In four treatment groups (n = 10), each bird was given a single oral dose (20 mg/kg) of a TLM formulation
after overnight fasting, and in four control groups (n = 5), the vehicles of those formulations or distilled water were given. Plasma TLM
concentrations were analyzed using an HPLC method and the related PK parameters (Cmax, Tmax, AUC0–∞, t1/2, kel, ClB/F, MRT, and Vd/F)
were obtained by noncompartmental analysis. The relative bioavailability of TLM-SLNs, TLM-NLCs, and TLM-LNCs were 1.7, 2.7, and
3.6 times, respectively, more than the BA of TLM-PH. Mean Cmax values were 1.21, 1.58, 1.76, and 2.17 µg/mL for TLM-PH, TLM-SLN,
TLM-NLC, and TLM-LNC, respectively. In conclusion, TLM-LNPs improved drug BA and PK parameters, especially the TLM-LNC
formulation, which suggests an efficient delivery system for TLM.
Key words: Tilmicosin, lipid nanoparticles, pharmacokinetics, bioavailability, chicken

1. Introduction
Tilmicosin (TLM) is a broad-spectrum macrolide antibiotic
derived from tylosin that is used in animals only. It has
been approved for the treatment and control of respiratory
diseases associated with Mycoplasma gallisepticum,
Mycoplasma synoviae, and various bacteria such as
Staphylococcus spp. and Pasteurella multocida in broiler
chickens. Generally, gram-negative Enterobacteriaceae are
resistant to TLM (1–4).
TLM is poorly water-soluble, especially in basic
mediums. At present, soluble tilmicosin phosphate (TLMPH) is used in veterinary medicine as an oral solution
but this form has problems of low potency and low
bioavailability (BA). High doses of TLM may enhance
its efficacy but pose the risk of acute cardiac toxicity
since the severity of TLM toxic effects is dose-dependent
(5,6). Given these disadvantages, studies on new delivery
systems for TLM are warranted.
* Correspondence: arasooli@ut.ac.ir
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Oral administration of drugs is considered the easiest
and most practical route but the gastrointestinal (GI)
epithelium acts as a physical barrier and may reduce
drug absorption and produce poor oral BA. To overcome
these problems, a number of new delivery systems have
been developed (7,8). Oral BA of drugs is highly affected
by their solubility and permeability, the most important
physicochemical parameters that determine drug
absorption (8). On the other hand, the BA of a drug usually
determines its therapeutic efficacy because it may affect
the onset, intensity, and duration of action of the drug (1).
Lowering particle size has revealed promise for
increasing the dissolution of drugs as well as their BA
since it can facilitate the delivery of drugs at the right
place and time. Nanoparticle (NP) delivery systems can be
prepared using biodegradable materials such as lipids (5).
These nanoparticles, which should be stable and nontoxic,
can improve the efficacy and safety of loaded drugs (8).
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The size and surface properties of NPs highly affect their
cellular internalization (9). In recent decades, lipid-based
nanoparticles (LNPs) have attracted special interest due to
the use of natural or synthetic lipids in their formulation,
which demonstrate high drug biocompatibility and
controlled release characteristics.
Nanoparticles can augment a drug’s absorption by
enhancing its dissolution, decreasing gastric emptying
rate, and improving drug intestinal permeability. Lipids
are recognized as agents that increase lymph formation
and encourage lymph flow (10). Basically, the body takes
up the lipid and the solubilized drug at the same time.
Therefore, it can be considered as a kind of “Trojan horse”
effect (11).
Oral LNPs are able to assist in drug dissolution and
solubilization because of their ability to protect drugs in
a solubilized condition and facilitate their mixing with GI
solubilizers such as bile acids. Furthermore, the protective
effects of LNPs along with their sustained release properties
save drugs from degrading conditions and improve their
stability in the GI tract. The nanoscale range of LNPs
facilitates their absorption into microfold cells (M cells) of
Peyer’s patches and eventually into the lymphatic system,
thus contributing to bypass the first-pass metabolism (12).
LNPs including solid lipid nanoparticles (SLNs),
nanostructured lipid carriers (NLCs), and lipid-core
nanocapsules (LNCs) are colloidal carriers composed of
a lipid matrix that is solid or liquid at body temperature.
The efficiency of LNPs is highly influenced by their
composition; they are usually composed of lipids and
surfactants and their structures affect the release properties
(13).
SLNs were incorporated as a novel oral drug delivery
system in the 1990s. Loading poorly water-soluble drugs
into SLNs can improve their GI solubilization, absorption,
and BA and provide controlled release properties as well
(9,14).
NLCs are considered as the second generation of LNPs
and incorporate a biocompatible solid lipid matrix and oily
lipid (15). These carriers have demonstrated high BA with
various routes of administration such as the oral route (7).
LNCs are a hybrid nanocarrier system with a vesicular
structure composed of a polymer and lipid. These
nanocapsules have great qualities as drug delivery systems
for the oral route and are able to increase the solubility of
lipophilic drugs, shield them from enzymatic degradation,
enhance drug BA, and decrease the side effects (16,17). In
addition, LNCs are more appropriate for prolonged release
(18). LNCs are different from other formulations in their
composition since LNCs have three main components
including the drug, lipid, and polymer. Proper interactions
between these components have a vital role in successful
manufacturing and efficacy of LNCs (17,19).

The objective of the present study was to perform a
pharmacokinetic (PK) analysis and compare the BA of
newly designed oral TLM-LNP formulations as potential
new delivery systems for TLM in chickens. The main PK
parameters of these LNP formulations were compared
with the conventional TLM-PH formulation and the
possible mechanisms were discussed.
2. Materials and methods
2.1. Chemicals and drug formulations
Tilmosin (tilmicosin phosphate aqueous solution, 250 mg/
mL) were provided from Rooyan Darou Pharmaceutical
Company (Semnan, Iran) and tilmicosin standard
(TLM content 97.3%) was kindly donated by Razak
Pharmaceutical Company (Tehran, Iran).
TLM-SLN, TLM-NLC, and TLM-LNC powders
were redispersed in distilled water to reach TLM
concentrations at 250 mg/mL of TLM. These TLM-LNP
formulations were prepared and their physiochemical
properties and antibacterial activities were evaluated at
the Nanotechnology center of the Faculty of Pharmacy of
Tehran University of Medical Science (TUMS). In vitro
antibacterial testing was carried out in the Laboratory
of Avian Microbiology and Laboratory of Pharmacology
of the Faculty of Veterinary Medicine (FVM). The LNP
preparations were in nanoscale range with suitable
properties as shown in Table 1.
TLM-PH and TLM-LNP formulations were diluted
with distilled water to a final concentration of 25 mg/mL
prior to oral administration to chickens.
2.2. Experimental animals
Sixty apparently healthy broiler chickens, aged 35 days and
weighing 1.0–1.2 kg, were obtained from the poultry farm
of the FVM of the University of Tehran. The broilers were
housed in cages with a 12-h dark/light cycle. Temperature
was maintained at 25 ± 2 °C and humidity at 45%–65%
with free access to balanced feed and water. The birds were
monitored for 1 week for any apparent clinical signs and
adaptation to the study area before administration of the
drugs. This study was approved by the ethics committee of
the FVM, Project Ethics No. 7506006-6-10.
2.3. Drug administration
The chickens were randomly divided into eight groups,
four test groups (n = 10) and four control groups (n = 5).
Birds were fasted for 12 h prior to drug administrations
and for 6 h after drug dosing but with free access to water.
The test groups were given a single oral dose of 20 mg/
kg of TLM-PH and TLM-LNP formulations equivalent to
20 mg/kg of TLM for TLM-SLN, TLM-NLC, and TLMLNC, respectively. Meanwhile, the control groups received
equal volumes of distilled water or SLN, NLC, and LNC
vehicles (blanks). Oral administration was done directly
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Table 1. Preparation, physicochemical properties, and MIC against S. aureus and E. coli of TLM-SLN, TLM-NLC, and TLM-LNC
formulations and TLM standard.
TLM standard

TLM-SLN

TLM-NLC

TLM-LNC

TLM (97.3%)

Hydrogenated castor oil as a solid
lipid matrix and polyvinyl alcohol
5% as a surfactant

Compritol 888 ATO as a solid lipid
matrix, sesame oil as a liquid oil,
and Poloxamer 407 and Tween 80
as surfactants

Eudragit S 100 as polymer, coconut
oil as oil core lipid and Span 80
and Tween 80 as surfactants

Entrapment efficiency (%)

66.3 ± 2.67

86.5 ± 2.17

94.0 ± 3.60

Zeta potential (mV)

–15.6 ± 3.21

–23.5 ± 1.13

–16.3 ± 2.51

Particle size (mm)

193.0 ± 2.64

156.6 ± 7.63

116.6 ± 7.63

97% drug
release within
12 h

Initial burst release (18%) within
first 2 h followed by a constant
sustained release for 120 h

Initial burst release (15%) within
first 2 h followed by a constant
sustained release for 200 h

Initial burst release (13%) within
first 2 h followed by a constant
sustained release for 200 h

S. aureus

1

1

0.5

0.5

E. coli

4

4

2

2

Composition

In vitro release (h)
at pH 7.4

MIC µg/mL

TLM-PH: Conventional tilmicosin phosphate solution; SLN: solid lipid nanoparticles; NLC: nanostructured lipid carriers; LNC: lipid-core nanocapsules.

into the middle of the esophagus using a gavage attached
to a syringe following the zero time-point blood sampling.
2.4. Blood sampling
Blood samples (about 1.5 mL) were collected from the
brachial or jugular vein into sterile heparinized tubes prior
to administration of different formulations (0 h) and at 1,
2, 4, 8, 12, 24, 48, 72, 96, and 120 h after administration.
Within 1 h after sample collection, the blood samples
were centrifuged at ∼3500 rpm (Eppendorf Centrifuge,
Model 5810 R, Germany) for 5 min. The harvested plasma
samples were stored at –20 °C until further use.
2.5. Sample preparation
To prepare plasma samples, 50 µL of perchloric acid was
added to 950 µL of each chicken plasma sample, vortexed
for 30 s, and centrifuged at ∼3500 rpm for 5 min. The
supernatant was transferred into a special glass tube and
20 µL of each sample was injected into the HPLC system
for analysis (1).
2.6. HPLC analysis
TLM concentrations in plasma were measured using
an HPLC system (Waters, USA), which consisted of
a multisolvent pump, solvent degasser, UV detector,
autosampler, interface, and Chromate software. The HPLC
column was C18 (5 µm particle size, 125 × 4.6 mm). The
modified methods of Clark et al. (20) and Eraslan (3) were
used for determination of TLM concentrations in plasma.
HPLC analysis was conducted using a mobile phase
consisting of 0.2 M ammonium acetate (pH 5), water,
acetonitrile, and methanol (20:32:24:24). Mobile phases
were filtered under vacuum through a 0.45-µm membrane
filter. Chromatographic separation was achieved at a flow
rate of 1 mL/min using UV detection at 291 nm (3,20).
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A TLM stock solution of 1.0 mg/mL was prepared
by adding 10 mg of TLM standard to 10 mL of
acetonitrile:water (1:1, v/v). Then it was further diluted in
chicken plasma to yield 0.01, 0.05, 0.1, 0.5, 1, and 5 µg/mL.
The HPLC method for TLM in chicken plasma was
validated by assessing the linearity, accuracy, precision,
recovery, selectivity, and sensitivity according to
performance criteria for method validation (3). A standard
calibration curve was provided by using six concentrations
of TLM (0.01–5 µg/ml) and it was used for calculation of
TLM levels in plasma samples.
2.7. Pharmacokinetic analysis
TLM plasma concentration data of each bird were used
to depict its concentration-time profile. The maximal
plasma concentration of drug (Cmax) and the time to reach
Cmax (Tmax) were directly obtained from the observed
concentration versus time profiles. Noncompartmental
analysis was used to estimate the PK parameters (AUC0–∞,
t1/2, Vd/F, ClB/F, kel, and MRT). The linear trapezoidal rule
was used to calculate areas under concentration-time
curves from 0 to 120 h (AUC0–120) and from 120 h to infinity
(AUC120–∞) using the following equation: AUC120–∞ = last
Cp/kel. The Rel. BA was calculated by using the following
equation and PK parameters obtained using Excel 2013.
Rel.BA =

AUC (0-∞) of TLM-LNP formulation
AUC (0-∞) of TLM-PH formulation

2.8. Statistical analysis
Data were expressed as mean ± SD and analyzed with SPSS
19. The differences in PK parameters were analyzed using
one-way ANOVA and Tukey’s test (P < 0.05).
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3. Results
The calibration curve for HPLC analysis of TLM was linear
over the range of 0.01–5 µg/mL as indicated by R2 = 0.999.
The calculated limit of detection (LOD) in chicken plasma
was 0.005 µg/mL and the limit of quantification (LOQ) was
0.015 µg/mL. At TLM concentrations of 0.1, 1, and 5 µg/
mL, the recovery rates were 99.6 ± 9.8%, 101 ± 7.5%, and
100 ± 3.7%, respectively, and the precision of the method
as expressed by RSD% of interday and intraday assays were
4.08, 3.30, and 3.46 and 3.06, 4.05, and 3.74, respectively.
TLM was well tolerated by the chickens without any
noticeable events. The major PK parameters and mean
concentration-time profiles for TLM-PH, TLM-SLN,
TLM-NLC, and TLM-LNC formulations are shown
in Table 2 and the Figure, respectively. There was no
detectable peak corresponding to TLM retention time in
the plasma samples of control groups.
The Cmax mean value of TLM-LNC and other TLMLNPs formulation was significantly higher than that
of TLM-PH (P < 0.05). In general, the mean values of
AUC0–∞, t1/2, kel, ClB/F, Vd/F, and MRT for various TLMLNP formulations were significantly different from those
of TLM-PH (P < 0.05). The AUC0–∞ values after oral
administration of TLM-LNPs were significantly higher
than those of TLM-PH (P < 0.05).
4. Discussion
In the present study, we compared TLM-loaded NPs with
the conventional formulation, TLM-PH. It was found that
all TLM-loaded NPs had significantly higher systemic BA
than the TLM-PH.

There are many possible mechanisms for increased oral
BA of TLM by using LNP formulations. In general, LNPs
are incorporated solid or liquid lipids similar to the fat
existing in food. Lipids can stimulate secretion of gastricpancreatic lipases and colipases. Consequently, according
to their residence time, a large amount of ingested lipids
are already analyzed in the GI tract (15). The absorption
of fatty acids or mono- and diacylglycerides that are
available in LNP formulations or made following digestion
by GI lipase may facilitate oral absorption of drugs (21).
Besides, the release of biliary lipids and salts is stimulated,
which in turn enhances the production of mixed micelles,
which include solubilized drug molecules. As a result,
by participation in mixed micelles, TLM-LNPs could be
better absorbed through the lymphatic system (15). The
relatively lower absorption of TLM-SLN and TLM-NLC
formulations in comparison with TLM-LNCs may be
explained by the lower ability of young chickens to digest
long-chain fatty acids (C14 to C24) existing in hydrogenated
castor oil and Compritol 888 ATO. In contrast, the
higher BA of the TLM-LNC formulation may be due to
the higher affinity of GI lipases in broilers for short- and
medium-chain fatty acids (C6 to C12), which are the main
components of its lipid, coconut oil (22).
The oral BA of TLM increased from 1.66-fold in
TLM-SLNs to 3.61-fold in TLM-LNCs, which correlated
inversely with the particle size of LNPs as it decreased from
193.0 ± 2.64 nm (SLNs) to 116.6 ± 7.63 nm (LNCs). The
nanoscale range of LNP formulations leads to a decrease
in particle size and highly increases their surface area (15).
In addition, the reduction in particle size is positively

Table 2. Pharmacokinetic parameters of TLM in chickens after oral administration of a single dose of TLM-PH, TLM-SLN, TLM-NLC,
and TLM-LNC formulations (20 mg/kg body weight). Data are expressed as mean ± SD (n = 10). Data followed by different letters (a,
b, c, d) differ significantly (P < 0.05).
PK parameter

TLM-PH

TLM-SLN

TLM-NLC

TLM-LNC

AUC0–∞ (µg h/mL)

43.0 ± 2.5 d

71.5 ± 5.8 c

116.4 ± 17.8 b

155.1 ± 8.6 a

t1/2 β (h)

29.3 ± 2.6 c

39.8 ± 3.9 b

46.5 ± 5.0 a

41.3 ± 3.4 b

Vd/F (L/kg)

20.4 ± 2.0 a

10.3 ± 2.7 b

11.9 ± 1.5 b

7.84 ± 2.6 b

MRT (h)

42.0 ± 3.8 b

50.3 ± 5.8 a

67.2 ± 8.8 a

59.6 ± 0.1 a

ClB/F (mL/min kg)

0.48 ± 0.10 a

0.29 ± 0.04 b

0.19 ± 0.05 c

0.14 ± 0.04 d

kel (h–1)

0.03 ± 0.01 a

0.03 ± 0.01 a

0.01 ± 0.01 c

0.02 ± 0.01 b

Tmax (h)

2.40 ± 0.24 c

5.60 ± 0.67 b

4.80 ± 0.80 b

12.00 ± 0.00 a

Cmax(µg/mL)

1.21 ± 0.09 b

1.58 ± 0.22 a

1.76 ± 0.38 a

2.17 ± 0.30 a

Rel. BA (F) %

100

166.2

270.7

360.7
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Plasma concentration (μg/mL)

TLM-PH
TLM-SLN

2.5

TLM-NLC
TLM-LNC

2
1.5
1
0.5
0

0

20

40

60

80

100

120

140

Time (h)

Figure. Plasma concentration vs. time curves of TLM after a single oral administration of
TLM-PH, TLM-SLN, TLM-NLC, and TLM-LNC formulations (20 mg/kg B.W.) in broiler
chickens. Each value represents the mean and SD (n = 10).

related to an adequate and steady absorption of TLM in
the GI tract. In general, the increase in the bioadhesion
of these LNP formulations to the GI wall leads to prolong
their residence time and their contact with epithelial
membranes, which improves their absorption (21). The
reduction in particle size may also lead the GI system to
uptake them by other routes, such as entry to submucosal
tissues through intracellular pathways. The process of GI
uptake may include diffusion of particles through mucus
and being more accessible to enterocyte surfaces, epithelial
interactions, and cellular trafficking (7).
Negative surface charges (zeta potential, ZP) of TLMLNP formulations can be considered as another possible
mechanism for enhancement of TLM oral BA. In general,
the glycocalyx renders the intestinal mucosa a negative
charge, with which it will attract positively charged
nanoparticles. Therefore, the intestinal mobility of particles
seems to be highly related to their surface charges, which
are inversely related to particle surface charge potentials.
With negatively charged particles, higher transport rates
can be expected in comparison to near neutral or positively
charged particles, whose transport will be highly limited
because of particle aggregation and electrostatic adhesive
interactions with intestinal mucin fibers. Increasing
the efficiency of the penetration through the intestinal
mucosa is important to improve oral delivery systems.
Nanoparticles should be sufficiently small to avoid severely
steric inhibition and adhesion to the intestinal fiber mesh.
On the other hand, NPs should have some mucoadhesion
to prolong their retention time and contact with intestinal
mucosa (8). In addition, the surface charge of NPs also
plays an important role in M cell uptake. For instance, it
has been reported that negatively charged NPs had higher
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M cell uptake than positively charged NPs (23). However,
the TLM-NLC formulation did not achieve higher AUC
values compared to the TLM-LNC formulation in spite
of showing higher ZP values (–23.5 ± 1.13 mV), because
the particles size and their surface charges are working
together in intestinal absorption processes, and TLM-LNC
had more ideal characteristics with regard to its smaller
particle size (116.6 ± 7.63 nm) with optimal ZP value
(–16.3 ± 2.51 mV).
LNPs can also enhance absorption of TLM through
lymphatic flow. They can induce lipoprotein production
and lymphatic lipid flux to augment the level of lymphatic
TLM transportation, which is significantly affected by
the lipid and surfactant types (21). The absorption by M
cells of Peyer’s patches is an additional way for lymphatic
transport of LNPs (12). The small size of LNPs allows for
more efficient absorption, particularly in the lymphoid
system, consequently bypassing the possible liver first-pass
metabolism (19). Although highly lipophilic compounds
such as long-chain triglyceride lipids can easily reach
systemic circulation by the lymphatic vessels, nevertheless,
particle size persists as the most vital factor in lymphatic
absorption (24). Particles with larger sizes may last longer
in Peyer’s patches, whereas smaller NPs are transported
directly to the thoracic duct, especially when NPs are
coated by polymers, leading them to be easily captured
by lymphatic vessels (24). Therefore, it seems that small
particle sizes of TLM-LNCs with their polymeric structure
are responsible for enhancing lymphatic uptake and
increasing the BA.
Furthermore, nonionic surfactants such as Poloxamer
407 and Tween 80 are other factors that may increase the
BA of TLM-LNC and TLM-NLC formulations due to
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the ability of these surfactants to improve their intestinal
permeability by disturbing the cellular membranes and
opening the tight junctions of intestinal epithelial cells
(15) and facilitating paracellular transportation of LNPs
(10). Surfactants can also contribute to the improvement
of the affinity between LNPs and the intestinal epithelial
membranes, and can enhance their bioadhesion to
the GI wall (19). These surfactants are favored for oral
formulations and efficiently reduce the degradation of
LNPs in the GI tract. The polyethylene oxide (PEO) chains
in these surfactants hamper the anchoring of the lipase/
colipase complex that is in charge of lipid degradation.
By providing sterically stabilizing layers with different
thicknesses of PEO chains on LNP surfaces, the in vivo
degradation rate of the lipid matrix can be adjusted and
slowed down and the LNPs can be given time to be absorbed
(13). In addition, Tween 80 can increase intestinal uptake
due to its ability to inhibit the p-glycoprotein efflux pump
(25). The results of the present study regarding the higher
efficiency of LNCs in improvement of PK properties are in
line with the findings of Bendera et al., who reported that
Tween 80 can be used to deliver drugs efficiently to the
brain and to inflamed tissues (16).
The presence of both surfactants, Poloxamer 407 and
Tween 80, as ingredients of TLM-LNCs and TLM-NLCs
may have contributed to the quality of these formulations,
and as a result increased their AUC and Cmax values much
more than those of TLM-SLNs and TLM-PH. These
surfactants may act by decreasing the degradation of these
formulations, prolonging TLM release and enhancing
their crossing through the intestinal barrier.
Indeed, Eudragit S 100, which was used to coat TLMLNCs, is a polymer with pH-dependent solubility. It
releases the drug in GI regions with pH of >7 like the large
intestine and colon (8), where it gets gradually soluble.
Eudragit S 100 has been used to entrap insulin to protect
it from degradation by GI juices and to permit it to be
released in GI regions with pH of >7, where proteolytic
enzymes are in low levels (26). Therefore, Eudragit S 100
served as a potential oral carrier in TLM-LNC formulations
in the present study. In addition, Mohammadzadeh et al.
demonstrated the efficiency of Eudragit S 100 in decreasing
p-glycoprotein activity and efflux process. It seems that
this polymer improved the BA of TLM by dual actions
(27). Generally, the presence of a polymeric coating wall
provides a protective layer against the harsh environment
of the GI tract such as proteolytic enzymes and may prolong
the exposure of TLM-LNCs with intestinal epithelial cells;
consequently, it may enhance the BA of TLM (17).
The relatively high BA of TLM-NLCs in the present
study is in accordance with the findings of Aburahma and
Badr-Eldin, since sustained release with little degradation/
aggregation behavior had been demonstrated by using

Compritol 888 ATO because of its long-chain fatty acids
(23,28). On the other hand, Severino et al. reported that
medium-chain triglycerides lipids are more effective than
long-chain triglycerides with regard to sustained release
(11), which seems closer to the results of the present study,
especially with regard to TLM-LNCs, in which coconut oil
constitutes its oily core.
Although hydrogenated castor oil in TLM-SLNs was
an effective nanoparticle system for controlled release and
improvement of PK characteristics of loaded drugs (14), it
achieved the least optimal PK parameters values. This may
be due to its more rapid degradation in the GI tract, which
leads to an increased rate of TLM release (6). Many other
factors may have also contributed to decreased TLMSLN absorption, such as their relatively higher particles
size (193.0 ± 2.64 nm) and lower ZP (–15.6 ± 3.21 mV).
However, Han et al. (6) suggested that the high initial
release rate of TLM from SLN might be helpful because it
reaches a therapeutic level quickly.
The TLM release by TLM-LNPs was slowed down
just to reach therapeutic serum levels so that the blood
concentrations did not reach toxic levels and this obviated
adverse effects such as cardiotoxicity induced by high doses
of conventional TLM (6). Using TLM-LNPs decreased
the TLM plasma elimination rate, as indicated by higher
elimination of t1/2 and increased MRT, which caused a
longer stay for TLM in blood circulation.
Abu-Basha et al. also studied the BA and PK parameters
of TLM in chickens using Provitil orally at 30 mg/kg B.W.
The average AUC0−72 was 24.2 ± 3.9 µg h/mL, Cmax was
2.09 ± 0.37 µg/mL, and Tmax was 3.99 ± 0.84 h. In spite of
using a 1.5-fold higher dose, the values reported for PK
parameters were much lower than those of the TLM-LNC
formulation, especially with regard to AUC values (1).
Keleş et al. also investigated the PK and tissue
concentrations of TLM after oral administration of a single
dose (50 mg/kg, B.W.) in fowl. TLM was slowly eliminated
from the serum and lungs with t1/2 of 30.2 ± 2.4 and 75.7
± 3.7 h, respectively. The mean Cmax was 6.2 times greater
in the lungs (7.96 ±0.30 µg/mL) than that in serum (1.28
± 0.04 µg/mL) with Tmax at 17.78 ± 7.51 h and 4.66 ± 2.0
respectively (29).
It is expected that TLM-LNCs followed by TLM-NLCs
can demonstrate better in vivo antibacterial activity due to
their higher AUC, Cmax, and sustained release properties
(14). In spite of their sub-MIC plasma concentrations
against E. coli, it seems that TLM-LNPs may be more
active than TLM-PH, since the clinical efficacy of TLM
formulations not only was affected by plasma drug levels
but also was related to intracellular TLM penetration,
which usually tends to be more accumulated within avian
phagocytic cells (30), like macrophages, monocytes, and
heterophils. Furthermore, TLM has high postantibiotic
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and sub-MIC effects, which could slow disease
development by allowing the immune system to eliminate
bacterial infection (30). In general, TLM Cmax values of
all tested formulations detected in chicken plasma after
oral administration were higher than the MIC for M.
gallisepticum and M. synoviae (0.0125–0.1 µg/mL). These
values were also higher than the MIC of plasma TLM in
cattle against Corynebacterium pyogenes (0.04 µg/mL)
and S. aureus (0.78 µg/mL) (1). Consequently, the clinical
efficacy of tested TLM-LNP formulations is expected to be
highly satisfactory with the TLM-LNC formulation due
to their better PK parameters, followed by TLM-NLC and
TLM-SLN formulations.
In conclusion, the systemic BA of TLM was significantly
enhanced by using oral LNPs (TLM-SLNs, TLM-NLCs,
and TLM-LNCs) in comparison to conventional TLMPH in broiler chickens. Newly formulated TLM-LNPs
increased the AUC0–∞, Cmax, Tmax, and MRT values

depending on their particle size, particle surface charges,
and lipid and surfactant compositions. The best BA results
were achieved by the LNC formulation (3.6-fold), followed
by NLCs (2.71-fold), compared to TLM-PH. It seems that
the hybrid delivery system (LNCs) is more promising to
achieve a sustained release TLM formulation with higher
antibacterial activity and lower drug toxicity.
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